Fig. 1 · Structure

Documents & Downloads

RITA (NSC 652287)

Cat. No. A11931 CAS 213261-59-7

p53 activator

RITA, also referred to as NSC 652287, is a trycyclic thiophene derivative that binds to MDM2, disrupting the MDM2-p53 complex and subsequently activating p53 and inducing apoptosis.

In Stock

Publications for RITA

1 publication citing this product

  1. M Kobayashi, .et al. , Oncotarget, 2020, May 5;11(18):1653-1665 PMID: 32405340

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Radiolabeled RITA associated with a recombinant human p53 N-terminal fragment in band-shift assays, with albumin binding also observed. This does not establish cellular p53–HDM2 inhibition: a separate HCT116 study found no disruption of the complex with 1 µM RITA for 16 h in the presence of MG132. [1,2]

RITA also supported recombinant SULT1A1 activity in a phosphatase-coupled assay. This result is consistent with a proposed metabolic-activation component to its pharmacology; it does not establish p53 as its only target or directly identify the active metabolite. [3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Mdm2
p53

Cellular Effect

Cell Line Activity Value Description Reference
HCT-116 GI50 0.8 μM Growth inhibition of human HCT116 cells after 24 hrs by CCK8 assay [PMID: 28435526]

RITA (NSC 652287) Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of RITA (NSC 652287) from 4 published references. In vitro models include recombinant human SULT1A1 with sulfate donor PAPS; p53+/+ HCT116 human colorectal carcinoma cells.

RITA (NSC 652287) In Vitro Studies

In MCF-7 cells, 24 h RITA treatment at 0.5–5 µM increased p53 and cleaved PARP1 but did not reproduce nutlin-3a-mediated PARP1 protein reduction. MDM2 mRNA increased. Thus, p53 accumulation alone did not predict PARP1 depletion in this model. [4]

Radiolabeled RITA binding to the human p53 N-terminal fragment

Biochemical assay · Purified GST–human p53 N-terminus (residues 2–65), GST-tag control, human fibrinogen and human serum albumin [1]

[14C]-RITA formed a shifted complex with GST–Np53 and HSA, but not fibrinogen; GST alone showed weak interaction. Standard denaturation disrupted the complexes. These assays support association with a p53 fragment but do not alone establish inhibition of cellular p53–MDM2 binding.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Association with GST–Np53 versus protein controlsQualitative response Shifted [14C]-RITA complex with GST–Np53 and HSA; no fibrinogen complex; weak GST interaction[1]
Persistence of RITA/protein complexes under denaturing conditionsQualitative response Complexes disrupted under standard denaturation[1]

Literature-Reported Treatment Conditions

Treatment concentration
40 µM [14C]-RITA with 20 µM purified protein (2:1 molar ratio)
Exposure duration
30 min
Method
Incubation at 37°C followed by non-denaturing band-shift analysis; standard denaturation as a reversibility control.
Reported limits
Vehicle fraction and assay replicate count for Figure 1C–D are not specified in the inspected main-text methods/caption.
Methods and source locations

Compound reported in the paper: RITA (NSC 652287)

Evidence concerns the tested research material; it does not validate a current Adooq lot or establish clinical efficacy.

Figures 1C–D and 2B; Results, RITA Interacts With the N-Terminus of p53; Methods, Binding Assays With [14C]-RITA

Association with GST–Np53 versus protein controls: Autoradiography with Coomassie protein visualization — Figures 1C and 2B; N-terminal binding Results

Persistence of RITA/protein complexes under denaturing conditions: Band-shift assay under standard denaturing conditions — Figure 1D and corresponding Results

Recombinant SULT1A1 activity in the presence of RITA

Biochemical assay · Recombinant human SULT1A1 with sulfate donor PAPS [3]

A phosphatase-coupled assay detected increasing enzyme activity with increasing SULT1A1 in the presence of fixed RITA. This supports RITA serving as a sulfotransferase substrate; the readout does not directly identify a reactive metabolite or establish the sole cellular target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Sulfotransferase activity in the presence of fixed RITAQualitative response Activity increased with enzyme amount; mean ± s.d., n = 3 independent experiments[3]

Literature-Reported Treatment Conditions

Treatment concentration
2.5 µM RITA (Figure 2f); 0.2 mM PAPS (Methods)
Exposure duration
1 h
Method
37°C incubation; phosphatase-coupled Universal Sulfotransferase Activity Kit; absorbance detection at 620 nm.
Vehicle
RITA stock dissolved in DMSO; final assay DMSO fraction not specified.
Reported limits
Supplementary Figure 4g was not read. No kinetic constant or metabolite structure is extracted.
Methods and source locations

Compound reported in the paper: RITA (NSC 652287)

Evidence concerns the tested research material; it does not validate a current Adooq lot or establish clinical efficacy.

Figure 2f; Results, Metabolic mechanisms of small-molecule activation; Methods, SULT1A1 and BLVRB kinetic assays; Small molecules for validation assays

Sulfotransferase activity in the presence of fixed RITA: Phosphatase-coupled assay, ΔOD620 — Figure 2f and caption; kinetic assay Methods

RITA did not disrupt p53–HDM2 association in a cellular co-immunoprecipitation assay

Cell-based study · p53+/+ HCT116 human colorectal carcinoma cells [2]

RITA did not disrupt the p53–HDM2 interaction under the tested conditions, whereas nutlin-3 served as a disrupting comparator. This is a condition-specific negative result relevant to interpretation of RITA as a p53-pathway reagent.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HDM2 associated with immunoprecipitated p53Qualitative response RITA did not disrupt association; nutlin-3 disrupted association under the same MG132-containing conditions[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM RITA; 4 µM nutlin-3 comparator; 10 µM MG132 in all compared conditions
Exposure duration
16 h
Method
Anti-p53 DO-1 immunoprecipitation followed by immunoblotting for associated HDM2 and total precipitated p53; whole-cell extracts assessed.
Vehicle
DMSO control
Co-treatment
MG132 (10 µM) was present during RITA, nutlin-3 and control treatments; nutlin-3 was a separate comparator, not combined with RITA.
Reported limits
No replicate count or quantitative inhibition estimate supplied for Figure 6A in the inspected caption.
Methods and source locations

Compound reported in the paper: RITA (NSC 652287)

Evidence concerns the tested research material; it does not validate a current Adooq lot or establish clinical efficacy.

Figure 6A; Results, RITA does not disrupt the p53-HDM2 interaction; Methods, Inductions and drug treatments and Western blot analysis and immunoprecipitation

HDM2 associated with immunoprecipitated p53: Co-immunoprecipitation and immunoblotting — Figure 6A and corresponding Results

RITA stabilized p53 without reproducing nutlin-3a-mediated PARP1 reduction

Cell-based study · MCF-7 human breast cancer cells [4]

RITA increased p53 and cleaved PARP1, but did not reproduce the reduction in PARP1 protein seen with nutlin-3a. MDM2 mRNA increased after RITA. The negative PARP1 result prevents equating p53 accumulation with PARP1 depletion.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
p53 stabilization and PARP1 protein responseQualitative response p53 increased; cleaved PARP1 increased; no PARP1 reduction of the kind induced by nutlin-3a[4]
MDM2 transcript responseQualitative response MDM2 mRNA increased; mean ± SEM, n = 3 different experiments; no numerical fold change extracted[4]

Literature-Reported Treatment Conditions

Treatment concentration
0.5, 1 and 5 µM RITA; 0 µM control; separate 10 µM nutlin-3a comparator
Exposure duration
24 h
Method
Immunoblotting for p53 and PARP1 with GAPDH loading control; MDM2 qRT-PCR normalized to β-ACTIN.
Vehicle
Reagents dissolved in DMSO; final treatment DMSO fraction not specified.
Reported limits
Figure 2A blot replicate count is not separately specified; n = 3 different experiments applies to qRT-PCR panels B–C in the caption.
Methods and source locations

Compound reported in the paper: RITA (NSC 652287)

Evidence concerns the tested research material; it does not validate a current Adooq lot or establish clinical efficacy.

Figure 2A–C; Results, MDM2 is required for nutlin-3a-mediated reduction of PARP1 protein; Methods, Cell culture and reagents, immunoblotting and qRT-PCR

p53 stabilization and PARP1 protein response: Immunoblotting, GAPDH loading control — Figure 2A and corresponding Results

MDM2 transcript response: qRT-PCR normalized to β-ACTIN — Figure 2B and caption

RITA (NSC 652287) In Vivo Studies

In mice bearing p53+/+ HCT116 xenografts, a single 10 mg/kg intraperitoneal RITA dose altered tumor biomarkers at 24 h: p53 and DNA-damage-response phosphorylation increased, while HIF-1α, HDM2 and VEGF decreased relative to solvent controls. These endpoints do not establish tumor regression or survival benefit. [2]

Single-dose RITA changed HCT116 xenograft biomarkers

Animal study · Female NCr athymic mice, 6–8 weeks old, bearing bilateral p53+/+ HCT116 xenografts; eight mice per group [2]

At 24 h, RITA-treated tumors showed increased p53, phospho-Ser15-p53 and phospho-Ser139-γH2AX, with reduced HIF-1α, HDM2 and VEGF versus solvent controls. This is tumor pharmacodynamic evidence, not a tumor-regression or survival study.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor protein responseQualitative response p53, P-S15-p53 and P-S139-γH2AX increased; HIF-1α and HDM2 decreased relative to DMSO controls[2]
VEGF in tumor lysatesQualitative response Lower VEGF in RITA group; four plotted points per condition represent two tumors across two experiments[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single administration
Treatment course
Tumors assessed 24 h after administration
Vehicle
Solvent control, labeled DMSO in Figure 8. Exact formulation for the 10 mg/kg tumor experiment is not separately stated.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
RITA versus solvent control
10 mg/kg
Solvent control (DMSO label in Figure 8)At 24 h, RITA-treated tumors showed increased p53, phospho-Ser15-p53 and phospho-Ser139-γH2AX, with reduced HIF-1α, HDM2 and VEGF versus solvent controls. This is tumor pharmacodynamic evidence, not a tumor-regression or survival study.[2]
RITA versus solvent control
Model: Female NCr athymic mice, 6–8 weeks old, bearing bilateral p53+/+ HCT116 xenografts; eight mice per group
Reported limits: The PBS/10% DMSO/5% Tween 20 formulation is specified for a separate 25 mg/kg pharmacokinetic experiment and is not assigned to this 10 mg/kg experiment.
Methods and source locations

Compound reported in the paper: RITA (NSC 652287)

Evidence concerns the tested research material; it does not validate a current Adooq lot or establish clinical efficacy.

Figure 8A–B; Results, RITA induces p53 and γH2AX phosphorylation and blocks HIF-1α and VEGF expression in vivo; Methods, In vivo analysis

Tumor protein response: Immunoblotting with β-actin loading control; two representative tumors displayed — Figure 8A, caption and in-vivo Results

VEGF in tumor lysates: Tumor-lysate VEGF quantification — Figure 8B and caption

RITA versus solvent control · Figure 8A–B; Results, RITA induces p53 and γH2AX phosphorylation and blocks HIF-1α and VEGF expression in vivo; Methods, In vivo analysis

Specifications

Manufacturer Adooq Bioscience
Actions Activator
CAS Number 213261-59-7
Applications p53 activator
Formula C14H12O3S2
Molecular Weight 292.4
Synonyms NSC652287; p53 Activator III
SMILES
C1=C(SC(=C1)C2=CC=C(O2)C3=CC=C(S3)CO)CO

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 56 mg/mL (191.53 mM)
Water Insoluble
Ethanol 8 mg/mL (27.36 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

RITA (NSC 652287) Research References

  1. [1] Grinkevich VV, Vema A, Fawkner K, et al. Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule Frontiers in molecular biosciences (2022). PMID: 35720128 DOI: 10.3389/fmolb.2022.823195 Source material
  2. [2] Yang J, Ahmed A, Poon E, et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia Molecular and cellular biology (2009). PMID: 19223463 DOI: 10.1128/mcb.00959-08 Source material
  3. [3] Rees MG, Seashore-Ludlow B, Cheah JH, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action Nature chemical biology (2016). PMID: 26656090 DOI: 10.1038/nchembio.1986 Source material
  4. [4] Kobayashi M, Ishizaki Y, Owaki M, et al. Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line Oncotarget (2020). PMID: 32405340 DOI: 10.18632/oncotarget.27581 Source material

Publications

1 publication citing this product

  1. M Kobayashi, .et al. , Oncotarget, 2020, May 5;11(18):1653-1665 PMID: 32405340

Added to your cart

View Cart Checkout
Loading...